352 reports of this reaction
3.1% of all BARICITINIB reports
#4 most reported adverse reaction
RHEUMATOID ARTHRITIS is the #4 most commonly reported adverse reaction for BARICITINIB, manufactured by Eli Lilly and Company. There are 352 FDA adverse event reports linking BARICITINIB to RHEUMATOID ARTHRITIS. This represents approximately 3.1% of all 11,538 adverse event reports for this drug.
Patients taking BARICITINIB who experience rheumatoid arthritis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHEUMATOID ARTHRITIS is moderately reported among BARICITINIB users, representing a notable but not dominant share of adverse events.
In addition to rheumatoid arthritis, the following adverse reactions have been reported for BARICITINIB:
The following drugs have also been linked to rheumatoid arthritis in FDA adverse event reports:
RHEUMATOID ARTHRITIS has been reported as an adverse event in 352 FDA reports for BARICITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHEUMATOID ARTHRITIS accounts for approximately 3.1% of all adverse event reports for BARICITINIB, making it a notable side effect.
If you experience rheumatoid arthritis while taking BARICITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.